NCT03164876View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 20, 2017

Primary Completion Date

April 3, 2019

Study Completion Date

April 3, 2019

Conditions
Schizophrenia
Interventions
DRUG

AUT00206

4 capsules of 200mg AUT00206, twice daily, to take orally with food for 4 weeks

DRUG

Placebo

4 capsules of placebo, twice daily, to take orally with food for 4 weeks

Trial Locations (1)

Unknown

King's College London Institute of Psychiatry, Psychology and Neuroscience (IoPPN), London

Sponsors
All Listed Sponsors
collaborator

King's College London

OTHER

lead

Autifony Therapeutics Limited

INDUSTRY

NCT03164876 - Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers. | Biotech Hunter | Biotech Hunter